Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 E...

by Chow, Laura QM, Haddad, Robert, Gupta, Shilpa, Mahipal, Amit, Mehra, Ranee, Tahara, Makoto, Berger, Raanan, Eder, Joseph Paul, Burtness, Barbara, Lee, Se-Hoon, Keam, Bhumsuk, Kang, Hyunseok, Muro, Kei, Weiss, Jared, Geva, Ravit, Lin, Chia-Chi, Chung, Hyun Cheol, Meister, Amy, Dolled-Filhart, Marisa, Pathiraja, Kumudu, Cheng, Jonathan D, Seiwert, Tanguy Y
Published 2016

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

by Herbst, Roy S., Baas, Paul, Kim, Dong-Wan, Felip, Enriqueta, Perez-Gracia, Jose L., Han, Ji-Youn, Molina, Julian, Kim, Joo-Hang, Arvis, Catherine Dubos, Ahn, Myung-Ju, Majem, Margarita, Fidler, Mary J., de Castro, Gilberto, Jr., Garrido, Marcelo, Lubiniecki, Gregory M., Shentu, Yue, Im, Ellie, Dolled-Filhart, Marisa, Garon, Edward B.
Published 2020